Affirmed Therapeutics BV (NASDAQ:AFMD) shares saw an uptick in trading volume on Friday . 174,866 shares changed hands during mid-day trading, an increase of 62% from the previous session’s volume of 107,795 shares.The stock last traded at $2.77 and had previously closed at $2.95.

Several research firms have recently commented on AFMD. Leerink Swann cut shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 19th. Jefferies Group reduced their target price on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Thursday, May 19th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Affirmed Therapeutics BV in a research note on Wednesday, May 18th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Affirmed Therapeutics BV has an average rating of “Buy” and a consensus price target of $8.63.

The company’s 50 day moving average is $2.80 and its 200 day moving average is $3.44. The company’s market capitalization is $95.44 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.05. The business had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period last year, the firm posted ($0.19) EPS. Affirmed Therapeutics BV’s revenue was down 6.4% compared to the same quarter last year. On average, equities analysts forecast that Affirmed Therapeutics BV will post ($1.11) EPS for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.